Abstract
Overview
Introduction
Ulcerative colitis and Crohn' s disease are the primary constituents of
Inflammatory Bowel Disease, which is estimated to affect approximately 1.8
million people in the seven major markets. Eight years after the launch of
Remicade in Crohn' s disease the next generation of anti-TNF' s are poised for
approval, but the anti-TNF class will soon be under attack from novel cytokine
therapies.
Scope
- Ulcerative colitis and Crohn' s disease ten-year forecasts, contrasted
against estimated total brand sales
- Sales and volume estimates by indication from 2005-2015 for the US,
combined five major EU markets (France, Germany, Italy, Spain, UK) and Japan
- Analysis of late-stage pipeline products for Crohn' s disease and
ulcerative colitis
- Discussion of future events that affect the sales and volume of key brands
Highlights
The battle between Cimzia and Humira will depend on efficacy, convenience and
cost. Datamonitor believes Humira' s efficacy in all patient segments,
including low CRP patients and it' s wealth of safety data, added to the fact
that it has already been used off-label, will win out over Cimzia superior
dosing regime.
Patient segmentation is expected to be crucial in the future of IBD treatment.
The maintenance of clinical remission and mucosal healing should be considered
key outcomes, which should be targeted towards specific groups to aid product
differentiation.
Ulcerative colitis patients respond better than Crohn' s patients to 5-ASAs and
surgery, which can effectively be a cure, therefore Datamonitor predicts less
success for the biologics in ulcerative colitis. Companies should be aware
that IBD is estimated to be neither the most prevalent or profitable
indication for autoimmune biologics.
Reasons to Purchase
- Compare inflammatory bowel disease forecasts with total brand sales for
key existing products
- Estimate the size of the Crohn' s disease and ulcerative colitis markets to
2015
- Benchmark late-stage pipeline products against the market leader
View Cart
